Numen CSO (YC S23) • Rice/Oxford Alum • Rhodes Scholar (Texas & Magdalen, 2016) • zipper club (Indiana & BAV, 2019)
San Francisco, CA
Joined July 2012
- Tweets432
- Following770
- Followers430
- Likes4.7K
Tom Carroll retweeted
Operable setting (2026): sciencedirect.com/science/ar…
Inoperable setting (2023): cell.com/cancer-cell/fulltex…
In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!
Tom Carroll retweeted
🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:
Tom Carroll retweeted
The reason mRNA can't cure more diseases? Delivery.
We built NGX1 to deliver mRNA to any cell in the body using AI and multivalent physics.
Tom Carroll retweeted
Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: nej.md/4wh8FB9
Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? nej.md/4b67lZi
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer." The graph shows event-free survival. The trial name, KEYNOTE-B15/EV-304, is in parentheses after the title. The NEJM identity sits at the bottom.
Tom Carroll retweeted
Truly monumental day for the #Ross community. Congratulations to trailblazers and colleagues @IHamamsy and @OuzounianMD for simultaneous publication of their incredible manuscripts reaffirming the magic of the Ross Procedure in @JACCJournals
Tom Carroll retweeted
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
ir.revmed.com/news-releases/…
Tom Carroll retweeted
For the second year in a row, Parafilm has been recognized with the Nobel Prize in Chemistry 2025! 🏅
Tom Carroll retweeted
Delighted to share the final version of Richard Zhou's study on how the CD163 scavenger receptor cleans up after toxic haemoglobin spills out from our blood cells. An amazing grabber mechanism!
rdcu.be/ewPA2
Tom Carroll retweeted
Reminds me of one of the worst cases of scientific fraud ever:
>cardiologist fakes data showing better outcomes for patients who were given beta blockers before surgery
>Europe changes its medical guidelines based on this research
>turns out beta blockers increase risk of death by 27%
>might have killed up to 800,000 people
Great Q&A in Politico with James Heathers, who is leading the Medical Evidence Project to "find bad medical evidence before it kills people."
teapaw.org/Meaningness/status/193…
Tom Carroll retweeted
Check out what we're working on at Olio Labs!
70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men.
What is driving this difference?
We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out:
Tom Carroll retweeted
Today we report in @NatureMedicine the development of a base editing strategy for prion disease, currently a fatal and rapidly progressing neurogenerative condition with no effective treatment. @PrionAlliance @DevermanLab (1/13)
drive.google.com/file/d/1DVp…
Tom Carroll retweeted
I’m excited to introduce Collate and announce our $30M seed round.
We’re using AI to help solve one of the biggest problems for life sciences companies — the never-ending cycle of document creation and maintenance you need to do to stay compliant.
While running my first company, I experienced the burden of documentation that life science companies face – from R&D to commercial readiness. Then at YC, I was lucky enough to witness the transformative, inevitable nature of software and AI. There's a unique opportunity here to bridge my two worlds.
I'm thrilled to be building this alongside @nateps and @jigishjpatel. Thank you to our investors who have backed us with a $30M seed round: Satish Dharmaraj at Redpoint, @joshk at First Round and @saranormous at Conviction. And of course, YC.
To YC and @garrytan - thank you for the invaluable gifts: a family of GPs I'll always count on, a deeper appreciation for software's potential, and most preciously, the privilege of supporting so many remarkable founders on their journeys.
forbes.com/sites/alexkonrad/…
Tom Carroll retweeted
New #JITC article: Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers bit.ly/3Wclz3f
Tom Carroll retweeted
Scavenger receptor CD163 multimerises to allow uptake of diverse ligands biorxiv.org/cgi/content/shor… #biorxiv_biochem
Tom Carroll retweeted
NEW content online! Exploiting temporal aspects of cancer immunotherapy dlvr.it/T8Q0kd
Tom Carroll retweeted
Exactly 1,100 days after suffering a cardiac arrest on the pitch at Euro 2020, Christian Eriksen scores for Denmark at Euro 2024! 🇩🇰
What a story 👏
Tom Carroll retweeted
Cool new paper in Cell that ties together two fundamentals of cancer biology: cancer cells have high levels of lactate (due to the Warburg effect), and almost always find a way to inactivate the cell's best tumour suppressor, p53
Zong et al. found that lactate, from the microenvironment, is transferred onto p53 as a post-translational modification - this inhibits p53 by stopping it from binding to DNA
In a mouse model of colon cancer, β-alanine (an amino acid and sports supplement, which blocks p53 lactylation) boosts p53 function and prolongs mouse survival - especially when combined with the chemotherapeutic drug, doxorubicin:
Study: cell.com/cell/abstract/S0092…
